EVAX

Evaxion Biotech
EVAX

$2.99

5.08%

Market Cap: $16.7M

About: Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Employees: 49

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

8% more capital invested

Capital invested by funds: $1.22M [Q1] → $1.31M (+$94.2K) [Q2]

0.08% more ownership

Funds ownership: 0.79% [Q1] → 0.87% (+0.08%) [Q2]

0% more funds holding

Funds holding: 6 [Q1] → 6 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

368%

upside

Avg. target

$14

368%

upside

High target

$14

368%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 42 / 135 met price target	368%upside $14	Buy Reiterated	20 Sept 2024
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 42 / 135 met price target	368%upside $14	Buy Reiterated	16 Aug 2024
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 42 / 135 met price target	368%upside $14	Buy Reiterated	1 Aug 2024

See Analyst Rankings

Financial journalist opinion

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, launches an enhanced version of its clinically validated AI-Immunology™ platform with an update of its EDEN™ AI prediction model. Among other improvements, the model can now predict toxin antigens, allowing for the development of improved bacterial vaccines.

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

COPENHAGEN, Denmark, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new pre-clinical data demonstrating the ability of its novel EVX-B2 mRNA Gonorrhea vaccine candidate in eliminating gonorrhea bacteria by triggering a targeted immune response.

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Mads Kronborg - Vice President, Investor Relations & Communication Conference Call Participants Li Chen - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Chong Liu - Ladenburg Operator Good day and thank you for standing by.

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM.

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is proud to announce the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024. The EVX-01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma (skin cancer).

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

COPENHAGEN, Denmark, July 16, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today showcases improved performance of its key building block, EvaxMHC, within its AI-Immunology™ platform, at the 32nd Intelligent Systems for Molecular Biology (ISMB) conference taking place in Montreal, Canada, from July 12-16, 2024.

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

COPENHAGEN, Denmark, June 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives positive feedback on its recent patent application for a new type of personalized vaccine targets, underscoring its novelty and inventiveness.

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

COPENHAGEN, Denmark, June 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces publication of data from its Phase 1 dose escalation study of its lead personalized cancer vaccine candidate, EVX-01, for metastatic melanoma. The study results, published in the Journal for ImmunoTherapy of Cancer , demonstrated that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses. Further, EVX-01 immunization did not induce vaccine-related serious adverse events in patients co-administered with anti-PD1 therapy.

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Zacks Investment Research

Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now

Evaxion Biotecch (EVAX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now

See News Rankings